CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 100 filers reported holding CUE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $279,669 | -35.7% | 121,595 | +2.1% | 0.00% | – |
| Q2 2023 | $434,653 | -11.1% | 119,083 | -13.1% | 0.00% | – |
| Q1 2023 | $488,943 | +599.7% | 136,959 | +458.6% | 0.00% | – |
| Q4 2022 | $69,876 | +125.4% | 24,518 | +79.0% | 0.00% | – |
| Q3 2022 | $31,000 | -94.8% | 13,700 | -94.3% | 0.00% | – |
| Q2 2022 | $601,000 | +104.4% | 241,543 | +300.2% | 0.00% | – |
| Q1 2022 | $294,000 | -66.0% | 60,349 | -21.0% | 0.00% | – |
| Q4 2021 | $864,000 | +71.8% | 76,361 | +121.3% | 0.00% | – |
| Q3 2021 | $503,000 | -61.7% | 34,500 | -69.5% | 0.00% | – |
| Q2 2021 | $1,315,000 | -41.1% | 112,955 | -38.3% | 0.00% | – |
| Q1 2021 | $2,232,000 | -6.4% | 183,000 | -4.0% | 0.00% | – |
| Q4 2020 | $2,384,000 | -34.8% | 190,550 | -21.6% | 0.00% | -100.0% |
| Q3 2020 | $3,657,000 | -45.3% | 243,042 | -10.9% | 0.00% | -50.0% |
| Q2 2020 | $6,689,000 | +2377.4% | 272,882 | +1334.5% | 0.00% | – |
| Q1 2020 | $270,000 | – | 19,023 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 1,915,219 | $23,959,000 | 5.70% |
| Prosight Management, LP | 906,569 | $11,341,000 | 5.24% |
| P.A.W. CAPITAL CORP | 140,000 | $1,751,000 | 1.54% |
| Voss Capital, LLC | 220,714 | $2,761,000 | 1.39% |
| Robertson Stephens Wealth Management, LLC | 484,000 | $6,054,000 | 1.26% |
| Slate Path Capital LP | 1,483,619 | $18,560,000 | 1.00% |
| Nantahala Capital Management | 2,506,772 | $31,360,000 | 0.97% |
| PRECEPT MANAGEMENT LLC | 150,000 | $1,877,000 | 0.76% |
| SANDERS MORRIS HARRIS LLC | 193,591 | $2,449,000 | 0.56% |
| Rock Creek Group, LP | 100,014 | $1,251,000 | 0.51% |